Citations

Clear

5486 citation(s) found for "Yu, Stephen".

The impact of maternal malaria on newborns
Hartman, Tyler, Rogerson, Stephen J. , Fischer, Philip R.

Mayo Clinic

Annals of Tropical Paediatrics | November 26, 2010 | Volume: 30 | Issue: 4 | Pages: 271-282

10.1179/146532810x12858955921032 | PMID 21118620 Get It

Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia
Steensma, David P. , Sloan, Jeff A. , Dakhil, Shaker R. , Dalton, Robert J., Kahanic, Stephen P., Prager, Diane J., Stella, Philip J., Rowland, Kendrith M. , Novotny, Paul J. , Loprinzi, Charles L. , Steensma, David P

Mayo Clinic

Journal of Clinical Oncology | November 23, 2010 | Volume: 29 | Issue: 1 | Pages: 97-105

10.1200/jco.2010.30.3644 | PMID 21098317 Get It

Purpose Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA. Patients and Methods This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received darbepoetin alfa once every 3 weeks and were randomly assigned to receive either ferric gluconate 187.5 mg intravenously (IV) every 3 weeks, oral daily ferrous sulfate 325 mg, or oral placebo for 16 weeks. Results There was no difference in the erythropoietic response rate (ie, proportion of patients achieving Hb ≥12 g/dL or Hb increase ≥ 2 g/dL from baseline): 69.5% (95% CI, 61.9% to 76.5%) of IV iron-treated patients achieved an erythropoietic response compared with 66.9% (95% CI, 59.1% to 74.0%) who received oral iron and 65.0% (95% CI, 57.2% to 72.3%) who received oral placebo (P = .75). There were also no differences in the proportion of patients requiring red cell transfusions, changes in quality of life, or the dose of darbepoetin administered. Adverse events (AEs) tended to be more common in the IV iron arm: grade 3 or higher AEs occurred in 54% (95% CI, 46% to 61%) of patients receiving IV iron compared with 44% (95% CI, 36% to 52%) who received oral iron and 46% (95% CI, 38% to 54%) who received oral placebo (P = .16). Conclusion In patients with CAA, addition of IV ferric gluconate to darbepoetin failed to provide additional benefit compared with oral iron or oral placebo.
The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study
Andriole, Gerald L. , Bostwick, David G., Brawley, Otis W. , Gomella, Leonard G. , Marberger, Michael, Montorsi, Francesco , Pettaway, Curtis A. , Tammela, Teuvo L.J. , Telöken, Cláudio , Tindall, Donald J., Freedland, Stephen J. , Somerville, Matthew C. , Wilson, Timothy H., Fowler, Ivy L., Castro, Ramiro, Rittmaster, Roger S., Group, REDUCE Study, Larcher, Alessandro , Group, REDUCE Study

Mayo Clinic

Journal of Urology | November 13, 2010 | Volume: 185 | Issue: 1 | Pages: 126-131

10.1016/j.juro.2010.09.011 | PMID 21074214 Get It

Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma
Kelly, Jennifer L., Novak, Anne J. , Fredericksen, Zachary S., Liebow, Mark , Ansell, Stephen M. , Wang, Alice H., Call, Timothy G. , Cerhan, James R. , Doǧan, Ahmet , Witzig, Thomas E. , Kay, Neil E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 8, 2010 | Volume: 19 | Issue: 11 | Pages: 2847-2858

10.1158/1055-9965.epi-10-0581 | PMID 20855536 Get It

Abstract Background: The t(14;18)(q32;q21) translocation is the most commonly observed chromosomal translocation in non–Hodgkin's lymphoma (NHL), resulting in constitutive Bcl-2 expression and apoptosis inhibition. In addition, germline variation in both BCL2L11 (BIM) and CASP9, known regulators of apoptosis, has recently been linked to NHL risk. We conducted a comprehensive evaluation of 36 apoptosis pathway genes with risk of NHL. Methods: We genotyped 226 single-nucleotide polymorphisms (SNP) from 36 candidate genes in a clinic-based study of 441 newly diagnosed NHL cases and 475 frequency-matched controls. We used principal components analysis to assess gene-level associations, and logistic regression to assess SNP-level associations. MACH was used for imputation of SNPs in BCL2L11 and CASP9. Results: In gene-level analyses, BCL2L11 (P = 0.0019), BCLAF1 (P = 0.0097), BAG5 (P = 0.026), and CASP9 (P = 0.0022) were associated with NHL risk after accounting for multiple testing (tail strength, 0.38; 95% confidence interval, 0.05-0.70). Two of the five BCL2L11 tagSNPs (rs6746608 and rs12613243), both genotyped BCLAF1 tagSNPs (rs797558 and rs703193), the single genotyped BAG5 tagSNP (rs7693), and three of the seven genotyped CASP9 tagSNPs (rs6685648, rs2020902, and rs2042370) were significant at P < 0.05. We successfully imputed BCL2L11 and CASP9 SNPs previously linked to NHL, and replicated all four BCL2L11 and two of three CASP9 SNPs. Conclusion: We replicated the association of BCL2L11 and CASP9 with NHL risk at the gene and SNP level, and identified novel associations with BCLAF1 and BAG5. Impact: Closer evaluation of germline variation of genes in the apoptosis pathway with risk of NHL and its subtypes is warranted. Cancer Epidemiol Biomarkers Prev; 19(11); 2847–58. ©2010 AACR.
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling
Hildebrand, Joanne M. , Luo, Zhenghua , Price-Troska, Tammy, Ziesmer, Steven C., Lin, Wai, Hostager, Bruce S. , Ansell, Stephen M. , Cerhan, James R. , Bishop, Gail A. , Novak, Anne J. , Manske, Michelle K. , Slager, Susan L. , Witzig, Thomas E. , Cerhan, James R

Mayo Clinic

Journal of Experimental Medicine | November 2, 2010 | Volume: 207 | Issue: 12 | Pages: 2569-2579

10.1084/jem.20100857 | PMID 21041452 Get It

The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor (BAFF-R), modulate signaling cascades critical for B cell development and survival. We identified a novel mutation in TNFRSF13C, the gene encoding human BAFF-R, that is present in both tumor and germline tissue from a subset of patients with non-Hodgkin lymphoma. This mutation encodes a His159Tyr substitution in the cytoplasmic tail of BAFF-R adjacent to the TRAF3 binding motif. Signaling through this mutant BAFF-R results in increased NF-κB1 and NF-κB2 activity and increased immunoglobulin production compared with the wild-type (WT) BAFF-R. This correlates with increased TRAF2, TRAF3, and TRAF6 recruitment to His159Tyr BAFF-R. In addition, we document a requirement for TRAF6 in WT BAFF-R signaling. Together, these data identify a novel lymphoma-associated mutation in human BAFF-R that results in NF-κB activation and reveals TRAF6 as a necessary component of normal BAFF-R signaling.
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing
Feldman, Andrew L. , Smith, David I., Ansell, Stephen M. , Johnson, Sarah H. , Porcher, Julie C., Özsan, Nazan , Wieben, Eric D. , Eckloff, Bruce W., Vasmatzis, George , Doǧan, Ahmet , Smith, David I., Law, Mark E. , Feldman, Andrew L

Mayo Clinic

Blood | October 29, 2010 | Volume: 117 | Issue: 3 | Pages: 915-919

10.1182/blood-2010-08-303305 | PMID 21030553 Get It

Abstract The genetics of peripheral T-cell lymphomas are poorly understood. The most well-characterized abnormalities are translocations involving ALK, occurring in approximately half of anaplastic large cell lymphomas (ALCLs). To gain insight into the genetics of ALCLs lacking ALK translocations, we combined mate-pair DNA library construction, massively parallel (“Next Generation”) sequencing, and a novel bioinformatic algorithm. We identified a balanced translocation disrupting the DUSP22 phosphatase gene on 6p25.3 and adjoining the FRA7H fragile site on 7q32.3 in a systemic ALK-negative ALCL. Using fluorescence in situ hybridization, we demonstrated that the t(6;7)(p25.3;q32.3) was recurrent in ALK-negative ALCLs. Furthermore, t(6;7)(p25.3;q32.3) was associated with down-regulation of DUSP22 and up-regulation of MIR29 microRNAs on 7q32.3. These findings represent the first recurrent translocation reported in ALK-negative ALCL and highlight the utility of massively parallel genomic sequencing to discover novel translocations in lymphoma and other cancers.
Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions
Roberts, Rosebud O., Kantarci, Kejal , Geda, Yonas E. , Przybelski, Scott A. , Weigand, Stephen D. , Petersen, Ronald C. , Jack, Clifford R. , Knopman, David S. , Jack, Clifford R , Kantarci, Kejal , Geda, Yonas E

Mayo Clinic

Diabetes Care | October 28, 2010 | Volume: 34 | Issue: 1 | Pages: 184-186

10.2337/dc10-0602 | PMID 20980413 Get It

OBJECTIVE To investigate the association of type 2 diabetes with subcortical infarctions. RESEARCH DESIGN AND METHODS We investigated this association in subjects with type 2 diabetes (case subjects; n = 93) and without type 2 diabetes (control subjects; n = 186), matched by age, sex, and years of education. Participants were a subset of the Mayo Clinic Study of Aging (median age 79 years) who had undergone magnetic resonance imaging. RESULTS The frequency of subcortical infarctions was 39% in case subjects and 29% in control subjects (odds ratio 1.59 [95% CI 0.91–2.75]). The association was stronger in case subjects without treatment (2.60 [1.11–6.08]) and in case subjects with diabetes-related complications (1.96 [1.02–3.74]) compared with control subjects. CONCLUSIONS These findings suggest that untreated type 2 diabetes and type 2 diabetes with complications are associated with subcortical infarctions.
Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Reeder, Craig B. , Ansell, Stephen M.

Mayo Clinic

Blood | October 27, 2010 | Volume: 117 | Issue: 5 | Pages: 1453-1462

10.1182/blood-2010-06-255067 | PMID 20978267 Get It

AbstractSeveral novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.
Temporal response of canine flexor tendon to limb suspension
Sun, Yulong , Thoreson, Andrew R. , Cha, Stephen S., Zhao, Chunfeng, An, Kai‐Nan, Amadio, Peter C. , Cha, Stephen S.

Mayo Clinic

Journal of Applied Physiology | October 15, 2010 | Volume: 109 | Issue: 6 | Pages: 1762-1768

10.1152/japplphysiol.00051.2010 | PMID 20947711 Get It

Tendon disuse, or stress deprivation, frequently accompanies clinical disorders and treatments, yet the metabolism of tendons subject to stress deprivation has rarely been investigated systematically. The effects of stress deprivation on canine flexor tendon were investigated in this study. One adult canine forepaw was suspended for 21 or 42 days. Control forepaws were collected from dogs that had no intervention on their limbs and paws. The expression of collagen I and III was not significantly altered in the tendons disused for 21 days but was significantly decreased at 42 days ( P < 0.03). The expression of collagen II, aggrecan, decorin, and fibronectin was significantly decreased in the tendons in the suspended limbs at 21 days ( P < 0.002) and further reduced at 42 days. With stress deprivation, the expression of matrix metalloproteinase 2 (MMP2) was significantly increased ( P < 0.004) at 21 and 42 days. The expression of MMP3 was significantly decreased at 21 and 42 days ( P < 0.03). The expression of MMP13 was not altered with stress deprivation at 21 and 42 days. The expression of MMP14 was significantly increased at 21 days ( P = 0.0015) and returned to the control level at 42 days. Tissue inhibitor of metalloproteinase 1 (TIMP1) expression was decreased after the limbs were suspended for 42 days ( P = 0.0043), but not 21 days. However, TIMP2 expression was not significantly different from control at 21 or 42 days. Furthermore, the cross-sectional area of the stress-deprived tendons at 42 days was decreased compared with the control group ( P < 0.01). The intervention method in this study did not result in any alteration of stiffness of the tendon. Our study demonstrated that stress deprivation decreases the anabolic process and increases the catabolic process of extracellular matrix in flexor tendon.
Clinical Trials Data Collection: When Less Is More
Sargent, Daniel J. , George, Stephen L. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | October 5, 2010 | Volume: 28 | Issue: 34 | Pages: 5019-5021

10.1200/jco.2010.31.7024 | PMID 20921455 Get It